Company well-positioned for further progress and broadening of R&D pipeline Cash resources of approximately $455 million as of December 31, 2023 (unaudited) Expected cash runway, including proceeds from recent private placement, into 2H 2027 Top-line data readout from the Phase 3 trial evaluating
Continue Reading
Dr. Jeffrey Smith named Executive Vice President and Chief Medical Officer Dr. John Fann promoted to Senior VP, Process Sciences Seven new Vice Presidents appointed, underscoring commitment to leadership development VANCOUVER, British Columbia , Jan. 04, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc.
Continue Reading
